Oyster Point Pharma, Inc.
OYST evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OYST—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2022.
Tracking 2 pipeline candidates · 2 clinical trials · 1 FDA decision for Oyster Point Pharma, Inc..
Run Oyster Point Pharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oyster Point Pharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
6.5 months
OCF -$36M · Net income -$37M
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Oyster Point Pharma, Inc.'s lead drug candidate?
Oyster Point Pharma, Inc.'s most advanced tracked candidate is oc-01 (Phase 2) for Neurotrophic keratopathy (NK).
Who is the CEO of Oyster Point Pharma, Inc.?
Jeffrey Nau, Ph.D. is the chief executive officer of Oyster Point Pharma, Inc. (OYST).
What therapeutic areas does Oyster Point Pharma, Inc. focus on?
Oyster Point Pharma, Inc. develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.